Biobot Analytics provides wastewater-based epidemiology services that collect and analyze wastewater samples, run laboratory assays, and deliver dashboards and interpreted population-level trend data for infectious diseases and high-risk substances.
Published Oct 6, 2026
Market reports list Biobot among key players, but many such reports do not publish transparent methodology or source data. Treat market-share claims cautiously unless supported by audited revenue figures or procurement datasets.
| Starting Price | Not publicly listed (quote-based) | Not publicly listed for services (public dashboard exists) | Typically quote-based (service dependent) |
| Suitable for | Public health agencies seeking interpreted WBE insights and substance monitoring programs | Jurisdictions prioritizing standardized methods and public dashboards; national-scale pathogen monitoring | Buyers seeking large-scale lab infrastructure and a broad environmental testing portfolio |
| Key Strength | Established presence in U.S. WBE; coverage across multiple substances and infectious disease panels | Emphasis on public dashboarding and standardized national program workflows | Scale, wide lab network, procurement familiarity, broad testing menus |
| Key Weakness | Limited public pricing and security documentation; some public perception of reduced public reporting | May not focus on drug/substance monitoring; program constraints for certain buyers | May provide testing without specialized WBE interpretation or program design support |
—
Biobot vs Verily/WastewaterSCAN:
Biobot vs Eurofins: